Toggle navigation
COVID-19
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2022 AUA Annual Meeting
2022 Summit on Cancer Health Disparities
EHA2022 Congress
Digestive Disease Week 2022
2022 ASCO Annual Meeting
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
About Us
Advertisement
Advertisement
Advertisement
Jun
27
Today In Oncology
Ipilimumab Plus Nivolumab Improves Progression-Free Survival in Advanced Melanoma
Dabrafenib Plus Trametinib Receives FDA Approval for BRAF V600E–Mutated Solid Tumors
FDA Denies Authorization to Market JUUL Products
Study Predicts Cancer Cases and Deaths in Africa Could Double by 2040
Nivolumab/Cabozantinib vs Sunitinib in First-Line Treatment for Advanced RCC Overall Survival Analysis of CheckMate 9ER Trial
View More
Advertisement
